Solasia Pharma K.K.

TSE:4597.T

49 (JPY) • At close September 19, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) JPY.

2024 Q22024 Q12023 Q42023 Q32023 Q22023 Q12022 Q42022 Q32022 Q22022 Q12021 Q42021 Q32021 Q22021 Q12020 Q42020 Q32020 Q22020 Q12019 Q42019 Q32019 Q22019 Q12018 Q42018 Q32018 Q22018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q12015 Q42015 Q3
Revenue 601115733092206072957611327651869116747841561,0191606961208267671.344403.8742.0533.57930001.31920024.5641.902
Cost of Revenue 92104131311489129870313028011541109352143182819014206560000000000
Gross Profit -32-93-116421611293092254583248571505812631131,001132506166261111.344403.8742.0533.57930001.31920024.5641.902
Gross Profit Ratio -0.533-8.455-7.7330.5750.5210.5860.5090.7630.5920.7350.89910.3820.5490.3470.2550.750.7240.9820.8250.72510.31710.1450.1431111101111
Reseach & Development Expenses 1477695116999311741817017723204359258925283463255422260211243570410331151382.46105.297158.925126.836120.652102.62295.726156.418138.902116.627
General & Administrative Expenses 1582322632502792807125295035055815024314341,347360333391755447354311378230278174204.107169.945152.888120.074185.87598.976104.92898.599133.48396.854
Selling & Marketing Expenses -34-93-122000000000000000000000000000000000
SG&A 1241391412502792807125295035055815024314341,347360333391755447354311378230278174204.107169.945152.888120.074185.87598.976104.92898.599133.48396.854
Other Expenses 0000000000000000000000000000000000.00300
Operating Expenses 2712152363663783738299476736826047067906922,2726437966461,177707565554948640609325586.567275.242311.813246.91306.527201.598200.654255.017272.385213.481
Operating Income -303-308-352-324-217-245-519-723-629-600-356-701-720-642-2,214-633-734-534-177-575-516-494-882-615-598-325-585.222128.631-309.76-243.331-6.527-201.599-199.333-55.017-247.821-211.579
Operating Income Ratio -5.05-28-23.467-4.438-0.702-1.114-0.855-2.451-8.276-5.31-1.29-140.2-3.871-7.055-13.257-13.468-8.738-3.423-0.174-3.594-7.478-8.098-4.24-23.654-7.868-46.429-435.4330.318-150.882-67.989-0.0220-151.124-0.275-10.089-111.24
Total Other Income Expenses Net -5-102-914-23-163-6-21-13-8-17-12-12-31-9-21-6-14-7-2-1-0.605-0.669-1.262-4.065-17.822-2.068-6.493-5.777-5.702-3.475
Income Before Tax -308-318-350-333-203-247-519-739-626-606-358-700-733-650-2,231-645-746-537-176-584-537-499-896-622-600-325-585.828127.962-311.022-247.396-24.349-203.667-205.828-60.794-253.523-215.054
Income Before Tax Ratio -5.133-28.909-23.333-4.562-0.657-1.123-0.855-2.505-8.237-5.363-1.297-140-3.941-7.143-13.359-13.723-8.881-3.442-0.173-3.65-7.783-8.18-4.308-23.923-7.895-46.429-435.8840.317-151.496-69.124-0.0810-156.049-0.304-10.321-113.067
Income Tax Expense -8-8-7-2-6-6-19615891555-4019-5-619-4-461-8-5-5-510.26-6.381-6.374-6.307-8.124-7.265-5.7710.957-65.66316.317
Net Income -300-310-344-331-196-241-500-800-631-614-367-716-738-656-2,190-665-740-531-195-579-532-560-889-617-595-320-596.087134.343-304.648-241.089-16.225-196.402-200.057-61.752-187.86-231.372
Net Income Ratio -5-28.182-22.933-4.534-0.634-1.095-0.824-2.712-8.303-5.434-1.33-143.2-3.968-7.209-13.114-14.149-8.81-3.404-0.191-3.619-7.71-9.18-4.274-23.731-7.829-45.714-443.5170.333-148.392-67.362-0.0540-151.673-0.309-7.648-121.647
EPS -1.57-1.78-2.04-1.97-1.17-1.43-2.98-4.94-4.38-4.6-2.82-5.46-5.68-5.22-18.8-5.71-6.36-4.57-1.85-5.51-5.07-5.35-9.66-6.71-6.76-3.64-6.81.53-3.52-3.62-0.19-4.76-4.85-1.5-2.24-2.75
EPS Diluted -1.57-1.78-2.04-1.97-1.17-1.43-2.98-4.94-4.37-4.6-2.82-5.46-5.67-5.22-18.8-5.71-6.36-4.56-1.85-5.51-5.06-5.34-9.66-6.7-6.75-3.64-6.81.48-3.51-3.62-0.19-2.34-2.38-0.73-2.24-2.75
EBITDA -269-215-230-200-77-121-375-586-502-476-232-576-596-519-2,091-510-610-407-49-452-402-383-782-575-587-322-585.055128.793-309.614-243.1-5.8-201.349-199.133-54.467-247.497-211.476
EBITDA Ratio -4.483-19.545-15.333-2.74-0.249-0.55-0.618-1.986-6.605-4.212-0.841-115.2-3.204-5.703-12.521-10.851-7.262-2.609-0.048-2.825-5.826-6.279-3.76-22.115-7.724-46-435.3090.319-150.811-67.924-0.0190-150.973-0.272-10.076-111.186